Display options
Cite
Russo V, Rago A, Proietti R, et al. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2016;8(2):67-75doi: 10.1177/2042098616673990.
Russo, V., Rago, A., Proietti, R., Di Meo, F., Antonio Papa, A., Calabrò, P., D'Onofrio, A., Nigro, G., & AlTurki, A. (2017). Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Therapeutic advances in drug safety, 8(2), 67-75. https://doi.org/10.1177/2042098616673990
Russo, Vincenzo, et al. "Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence." Therapeutic advances in drug safety vol. 8,2 (2017): 67-75. doi: https://doi.org/10.1177/2042098616673990
Russo V, Rago A, Proietti R, Di Meo F, Antonio Papa A, Calabrò P, D'Onofrio A, Nigro G, AlTurki A. Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf. 2017 Feb;8(2):67-75. doi: 10.1177/2042098616673990. Epub 2016 Oct 24. PMID: 28255434; PMCID: PMC5315223.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Drug Saf. 2017 Feb;8(2):67-75. doi: 10.1177/2042098616673990. Epub 2016 Oct 24.

Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence.

Therapeutic advances in drug safety

Vincenzo Russo, Anna Rago, Riccardo Proietti, Federica Di Meo, Andrea Antonio Papa, Paolo Calabrò, Antonio D'Onofrio, Gerardo Nigro, Ahmed AlTurki

Affiliations

  1. Chair of Cardiology, Second University of Naples, Monaldi Hospital, Piazzale Ettore Ruggeri, Naples, Italy.
  2. Chair of Cardiology, Second University of Naples, Monaldi Hospital, Naples, Italy.
  3. Cardiology Department, Luigi Sacco Hospital, Milan, Italy.
  4. Department of Cardiology, Monaldi Hospital, Naples, Italy.
  5. McGill University Health Centre, Montreal, Quebec, Canada.

PMID: 28255434 PMCID: PMC5315223 DOI: 10.1177/2042098616673990

Abstract

The aim of our article is to provide a concise review for clinicians entailing the main studies that evaluated the efficacy and safety of target-specific oral anticoagulants (TSOAs) for thromboembolic stroke prevention in the real-world setting. Atrial fibrillation (AF) is one of the most common supraventricular arrhythmias that requires anticoagulation therapy to prevent stroke and systemic embolism. TSOAs, dabigatran, apixaban and rivaroxaban have become available as an alternative to warfarin anticoagulation in nonvalvular atrial fibrillation (NVAF). Randomized clinical trials showed non-inferior or superior results in efficacy and safety of the TSOAs compared with warfarin for stroke prevention in NVAF patients. For this reason, the 2012 update to the European Society of Cardiology guidelines for the management of AF recommends TSOAs as broadly preferable to vitamin K antagonists (VKAs) in the vast majority of patients with NVAF [Camm

Keywords: apixaban; atrial fibrillation; dabigatran; efficacy; novel oral anticoagulant; real life; rivaroxaban; safety; stroke

Conflict of interest statement

Conflict of interest statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  1. Med Devices (Auckl). 2015 Jan 29;8:103-14 - PubMed
  2. Thromb Haemost. 2012 Mar;107(3):584-9 - PubMed
  3. Eur Rev Med Pharmacol Sci. 2015 Apr;19(8):1461-79 - PubMed
  4. J Pharmacol Pharmacother. 2014 Jan;5(1):12-4 - PubMed
  5. Eur Heart J. 2016 Apr 7;37(14 ):1145-53 - PubMed
  6. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76 - PubMed
  7. Am J Med. 1993 Sep;95(3):315-28 - PubMed
  8. N Engl J Med. 2015 Aug 6;373(6):511-20 - PubMed
  9. J Am Coll Cardiol. 2011 Jan 11;57(2):173-80 - PubMed
  10. Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74 - PubMed
  11. Am Heart J. 2014 Mar;167(3):329-34 - PubMed
  12. Thromb Res. 2015 Oct;136(4):744-8 - PubMed
  13. Blood. 2014 Aug 7;124(6):955-62 - PubMed
  14. Thromb Haemost. 2016 Oct 28;116(5):975-986 - PubMed
  15. Curr Med Res Opin. 2014 Jul;30(7):1317-25 - PubMed
  16. Circulation. 2015 Jan 13;131(2):157-64 - PubMed
  17. J Am Coll Cardiol. 2013 Jun 4;61(22):2264-73 - PubMed
  18. Int J Cardiol. 2016 Dec 1;224:454-455 - PubMed
  19. N Engl J Med. 2015 Dec 17;373(25):2413-24 - PubMed
  20. Clin Cardiol. 2015 Feb;38(2):63-8 - PubMed
  21. N Engl J Med. 2011 Mar 3;364(9):806-17 - PubMed
  22. Thromb Haemost. 2016 Sep 28;116(Suppl. 2):S13-S23 - PubMed
  23. N Engl J Med. 2009 Sep 17;361(12):1139-51 - PubMed
  24. Int J Cardiol. 2015 Apr 1;184:283-4 - PubMed
  25. Cerebrovasc Dis. 2013;36(2):115-9 - PubMed
  26. N Engl J Med. 2013 Aug 29;369(9):799-808 - PubMed
  27. JAMA. 2015 Apr 14;313(14):1443-50 - PubMed
  28. PLoS One. 2015 Apr 29;10(4):e0125257 - PubMed
  29. Lancet. 2014 Mar 15;383(9921):955-62 - PubMed
  30. Dtsch Med Wochenschr. 2012 Jan;137(4):138-41 - PubMed
  31. Eur Heart J. 2012 Nov;33(21):2719-47 - PubMed
  32. Europace. 2016 Sep;18(9):1319-27 - PubMed
  33. N Engl J Med. 2011 Sep 15;365(11):981-92 - PubMed
  34. Thromb Haemost. 2013 Feb;109(2):328-36 - PubMed
  35. Curr Med Res Opin. 2014 Dec;30(12):2461-9 - PubMed
  36. Fundam Clin Pharmacol. 2015 Feb;29(1):10-20 - PubMed
  37. Europace. 2015 Oct;17(10):1467-507 - PubMed
  38. N Engl J Med. 2011 Sep 8;365(10):883-91 - PubMed
  39. Expert Rev Hematol. 2016;9(2):115-22 - PubMed
  40. J Am Coll Cardiol. 2013 Sep 3;62(10):900-8 - PubMed
  41. Clin Appl Thromb Hemost. 2014 Oct;20(7):665-72 - PubMed
  42. Eur Rev Med Pharmacol Sci. 2015 Oct;19(20):3961-7 - PubMed

Publication Types